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ABSTRACT 
 
Several models for prostate oncogenesis have been presented throughout the years, including the 
cancer stem cell (CSC) model.  CSCs may be responsible for the self-renewing properties, and 
therefore progression, of the tumor.  In this project, several protein and integrin markers were 
characterized using immunohistochemistry, immunofluorescence, and immunoblotting to 
identify cancer stem cells in human biopsy tissue.  The data suggest that α2 and Trop2 cannot be 
used to identify CSCs, and that using several markers simultaneously, including perhaps CD133,  
will be required to identify, and eventually isolate, cancer stem cells. 
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BACKGROUND 
 
Cancer Stem Cells 
Overview 
Discovered roughly fifteen years ago in hematopoietic cancer (Regenbrecht et al., 2008), 
cancer stem cells (CSCs) represent a small subset of cells in a tumor, and are different from the 
highly differentiated tumor cells (Morrison et al., 2008).  It is thought that CSCs arise from stem 
cells which undergo cancerous growth, while maintaining their ability to undergo differentiation 
like normal stem cells (Signoretti and Loda, 2007).  It is also theorized that CSCs could be the 
product of the transformation of transit-amplifying cells (unipotent progenitor cells), or from the 
de-differentiation of adult cells that have acquired characteristics of stem cells (Signoretti and 
Loda, 2007).  The cancer stem cell phenotype is defined by several distinct features that include 
self-renewal, differentiation, and extensive proliferation (Vaish, 2007).  For cancer stem cells 
post-cell division, one of the daughter cells has identical genetic content to the parent cell and 
each stem cell is capable of differentiating into multiple lineages (Vaish, 2007).  In recent years, 
cancer biologists have discovered that normal stem cells and cancer stem cells are similar, both 
phenotypically and functionally, as characterized in the hematopoietic system where 
hematopoetic stem cells (HSCs) and leukemic stem cells (LSCs) have been shown to express 
common cell surface markers (Yilmaz and Morrison, 2008).  Similarities between these two cell 
types are also seen in their self-renewal pathways (Yilmaz and Morrison, 2008).  This 
information is of great importance and relevance, as it promotes a clearer understanding of the 
self-renewal mechanism essential for tumor growth, allows for the identification of more specific 
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CSC markers, and reveals information about pathways that may be suitable as future treatments 
against cancer (Regenbrecht et al., 2008).   
Studies of cancer stem cells in solid tumors are still in the developmental stage 
(Regenbrecht et al., 2008).  Methods for the isolation of CSCs from solid tumors, as investigated 
in this MQP, have still yet to be established (Regenbrecht et al., 2008).  In cases where CSCs 
were successfully isolated from solid tumors, it is seen that they possess biological properties 
that directly correlate with patient prognosis (Regenbrecht et al., 2008).  In the brain tumor, it 
was reported that mechanisms of DNA damage repair are specifically activated in CSCs to 
confer resistance to radiation to them (Regenbrecht et al., 2008).  Thus, the identification and 
isolation of CSCs is the actual challenge for development of target therapies for cancer treatment 
(Regenbrecht et al., 2008). 
 
Cancer Stem Cell Model 
Several models have been postulated to explain the origin and continued growth of 
tumors.  The CSC hypothesis is derived from the fact that cancer cells do not form a 
homogenous population (Regenbrecht et al., 2008).  A heterogenous population of cancer cells 
could potentially result from the differentiation of a single stem cell.  It is believed that cancer 
stem cells form a small portion of the tumor cell population (Regenbrecht et al., 2008).  Studies 
performed on these particular cells indicate that they are the only cells within the tumor 
population that are capable of maintaining tumor growth indefinitely (Regenbrecht et al., 2008).   
There are several possible origins of cancer stem cells.  In the oldest theorized model 
(Lapidot et al., 1994), CSCs emerge from normal stem cells by mutations that allow for an 
unchecked growth of CSCs (Lobo et al., 2007).  In newer models, however, it is viewed that 
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CSCs may arise from primary cancer cells that have acquired the ability to self-renew, occurring 
when several oncogenic mutations confer self-renewal capability onto regular cancer cells (Lobo 
et al., 2007). 
 
Evidence for the Existence of CSCs 
Evidence for the existence of CSCs is provided by a mouse teratocarcinoma cancer 
model in which tumors arise from germinal totipotent stem cells.  This model provides a way by 
which scientists are able to study how the cellular environment contributes to oncogenesis (Lobo 
et al., 2007).  Upon transplantation, these germinal stem cells form tumors consisting of both 
young and developed cell components, providing a model for how tumors form into a 
heterogeneous population of cells, and making this model useful for studying how the niche 
affects tumorigenesis (Lobo et al., 2007). 
 
Prostate Cancer 
Cancer, a leading cause of death worldwide, causes one in every four deaths in the United 
States (Jemal et al., 2009).  Prostate cancer is the most common non-skin cancer among men in 
United States (American Cancer Society, 2009), and is the second leading cause of death among 
men (Crawford, 2003).  Almost 200,000 men in the country will be diagnosed with prostate 
cancer in 2010, leading to almost 28,000 deaths (Jemal et al., 2009).  Statistics show that 1 in 6 
men will be diagnosed with prostate cancer at one point in their lives, with the likeliness 
increasing with age (Prostate Cancer Foundation, 2009).  In fact, more than half of all prostate 
cancer cases are diagnoses of men 65 years and older (Prostate Cancer Foundation, 2009).   
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Despite these bleak numbers, the five-year survival rate for all stages of prostate cancer is near 
100% (American Cancer Society, 2007). 
Prostate cancer is thought to begin with a pre-cancerous state known as prostatic 
intraepithelial neoplasia (PIN) (American Cancer Society, 2009).  PIN is seen in men as young 
as 20 years old, and by the time they reach 50, 50% of men show this condition (American 
Cancer Society, 2009).  This condition shows physically noticeable changes in normal prostate 
gland cells, but at this point, abnormal cells would not be seen growing into other parts of the 
prostate, like cancerous cells (American Cancer Society, 2009).   
While the majority of prostate tumors grow slowly, when they metastasize, they can do 
so very quickly (American Cancer Society, 2007).  As such, prostate cancer often shows no early 
signs or symptoms (American Cancer Society, 2007).  It is common for the prostate gland to 
become enlarged through the course of a man’s life (National Kidney and Urologic Diseases 
Information Clearinghouse, 2006).  This natural process is known as benign prostatic 
hyperplasia, BPH.  Though having BPH does not increase the likelihood of developing prostate 
cancer, a man with BPH may have undetected prostate cancer as well, or may develop prostate 
cancer in the future (National Kidney and Urologic Diseases Information Clearinghouse, 2006).  
Since this enlargement process is natural and inevitable, age is the primary risk factor for 
prostate cancer (National Kidney and Urologic Diseases Information Clearinghouse, 2006). 
The normal prostatic epithelium is composed of three different types of cells: secretory, 
basal, and neuroendocrine (Signoretti et al., 2000).  Cells have been identified in the normal 
prostatic epithelium which are a morphological and immunophenotypical intermediate between 
basal and secretory cells (Signoretti et al., 2000).  Evidence has been shown that basal and 
secretory cells are independent lineages and each have the ability to self-renew (Evans and 
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Chandler, 1987). Thus, the existence of a prostate stem cell able to give rise to both basal and 
secretory cells is controversial (Signoretti et al., 2000). 
Though the prostate is composed of several types of cells, the majority of prostate 
cancers develop from the luminal secretory cells (American Cancer Society, 2009).  Other types 
of cancers that can also develop in the prostate are known as sarcomas, small cell carcinomas, 
and transitional cell carcinomas (American Cancer Society, 2009).  However, since the other 
types are so rare, most prostate cancers can be assumed to be adenocarcinomas (cancers 
developed from luminal epithelium) (American Cancer Society, 2009).  The human prostate 
cancer specimens evaluated in this MQP are adenocarcinomas.   
 
Prostate Cancer Stem Cells 
It has been postulated that prostate cancer arises from differentiated luminal cells, since 
most of the tumor cell population express luminal cell-specific markers, while being negative for 
basal markers (Lang et al., 2009; Signoretti et al., 2000).  This information has also led to the 
hypothesis that prostate cancer arises from intermediate progenitor cells which have gained the 
ability via mutations to self-renew (Lang et al., 2009).  It has also been suggested that prostate 
CSCs arise from once normal stem cells (Lang et al., 2009). 
 
Integrins in Cancer 
 
The integrin “superfamily” is composed of α and β heterodimeric transmembrane 
proteins that bind the extracellular matrix (ECM) to modulate cellular adhesion to substrate 
(Mizejewski, 1999).  ECM proteins are essential for the normal development and remodeling of 
tissues during morphogenesis, tissue maintenance, wound healing, and oncogenesis (Mizejewski, 
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1999).  Integrins are composed of long extracellular domains (see Figure 1 for structure), which 
mediate adhesion to their ligands, and short cytoplasmic domains which bind/interact with 
several receptors to the cytoskeleton and intracellular signaling proteins involved in the 
regulation of signaling networks, such as cytoskeletal functions (Hayes et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagram of Integrin Structure and Domains.  Integrin receptors are 
composed of two subunits (α and β).  The majority of amino acid residues are 
extracellular, and contain a variety of functional domains. (Goel et al., 2004) 
 
Integrin Deregulation in Prostate Cancer 
In prostate cancer, tumor cells show abnormal expression of integrins and have a 
significantly different ECM, compared to normal prostatic cells.  Integrin deregulation in cancer 
is thought to occur through activation of various specific transcriptional, translational and post-
translational processes (Goel et al., 2008). 
Studies have reported that most α and β integrin subunits are downregulated as a prostate 
gland slowly turns cancerous.  Specifically, several reports show that the α3, α4, α5, and α7 
subunits are downregulated (Goel et al., 2008).  Integrin α2 is unique in that it is downregulated 
12 
 
in prostate cancer while being upregulated in lymph node metastases, when compared to primary 
lesions (Goel et al., 2008).   
In contrast to most integrins, αvβ3, αvβ6, and a truncated version of α||b are upregulated 
in prostate cancer (Goel et al, 2008).  In studies performed on two prostate epithelial cell lines, 
PC3 and LNCaP, it was seen that αvβ3 is expressed at high levels in PC3 as compared to LNCaP 
(Zheng et al., 1999). PC3 cells are able to form metastatic lesions and intraperitoneal tumors, 
while LNCaP cells can form tumors but do not metastasize (Zheng et al., 1999).  This suggests a 
correlation between αvβ3 expression and metastatic potential of prostate cancer cells (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Overexpression of Integrin αvβ3 in Metastatic Prostate Cancer 
Cells.  FACS analysis of αvβ3 integrin expression in two types of prostate cancer 
cell lines.  PC3 cells show high metastatic potential, while LNCaP cells show low 
metastatic potential. Vertical axis represents cell number, while horizontal axis 
represents αvβ3 fluorescence expression and intensity.  (Zheng et al., 1999) 
 
 
A summary of the disregulation of integrin α subunits in prostatic adenocarcinoma and 
metastases is shown in Table I.   
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Integrin disregulation during human prostate cancer progression     
            
α Subunit Sample; Method 
 
Deregulated Expression 
 
References 
  
    
  
α2 Tissue specimens; 
IHC 
downregulated in adenocarcinoma*; 
upregulated 
in metastases 
Nagle et al, 1994; 
Bonkhoff et al, 1993 
        
α3, α4 α5 Tissue specimens; 
IHC 
 downregulated in adenocarcinoma  Nagle et al, 1994 
        
α6 Tissue specimens; 
IHC,  
TEM 
 polarized distribution in benign, less polarized 
in 
HGPIN, not polarized in lymph node 
metastases; 
upregulated in metastases 
 Bonkhoff et al, 1993; 
Knox et al,  
1994; Nagle et al, 1995 
        
α7 Tissue specimens; 
IHC,  
Sequencing of 
genomic  
DNAs and cDNAs 
 downregulated in adenocarcinoma; also 
mutated  
in adenocarcinoma and recurrent 
adenocarcinoma 
 Ren et al, 2007 
        
α||b 
(truncated) 
Tissue specimens; 
IHC 
 expressed in adenocarcinoma; absent in 
normal tissue 
 Trikha et al, 1998 
            
            
Table 1.  Integrin Disregulation During Human Prostate Cancer Progression. 
(Goel et al., 2008) 
 
 
Transformation of a tumor cell from a benign state to a malignant one is characterized by 
the disruption of cytoskeletal organization, decreased cellular adhesion, and altered adhesion-
dependent reactions (Mizejewski, 1999).  The spatial arrangement of integrins becomes 
disordered, with a diffuse and sparse cellular distribution in carcinomas (Mizejewski, 1999).  
These cell-surface rearrangements can effect various integrin functions, such as ligand-binding 
affinity, and correlate with the disorganization of the membrane (Mizejewski, 1999).  Abnormal 
interactions with the ECM induce cell proliferation, migration, differentiation, and overall cancer 
progression (Fornaro et al., 2001).   
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Cancer Stem Cell Markers 
 
Integrins as CSC Markers for Prostate Cancer 
β3 Integrin 
          As previously described, β3 integrin, among other β subunits, is upregulated in human 
prostate cancer (Goel et al., 2008).  The β3 integrin subunit is known to localize in focal 
contacts, and also mediates the spreading and cytoskeletal rearrangement of normal, non-
cancerous cells (Goel et al., 2008).  However, ectopic overexpression of β3 does not affect cell 
spreading (Zheng et al., 1999), suggesting that the ability of β3 subunit to promote cancer 
progression is independent of on its effects on spreading (Goel et al., 2008).  It has also been 
concluded that the β3 subunit activates specific cell signaling pathways, and supports distinct 
cellular functions in cancer (Goel et al., 2008).  β3 has been shown to contribute to the 
establishment and growth of pulmonary metastatic melanoma lesions (Filardo et al., 1995).  This 
integrin has also been shown to increase the invasiveness of cutaneous melanomas from the 
epidermis to the dermis in studies performed by Hsu et al in 1998.  Studies have also shown that 
β3 is necessary in cancer cells for increasing the levels of downstream effectors such as cdc2 
(Manes et al., 2003).  Increased levels of cdc2 resulted in increased cell migration by its 
association with cyclin B2 and phosphorylation of caldesmon, a substrate of cdc2 (Manes et al., 
2003).  Both caldesmon and cdc2 are localized in the membrane ruffles of motile cells, playing a 
key role in cancer cell migration (Manes et al., 2003).  Thus, increased β3 levels result in an 
increase of cdc2 levels, which in turn, promotes cancer cell migration (Manes et al., 2003). 
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α2 Integrin 
α2 integrin is expressed in the basal layer of the normal human prostate (Knox et al., 
1994).  However, its expression becomes aberrant in prostate cancer.  In particular, it is 
downregulated in primary tumors and upregulated in lymph node metastases (Goel et al., 2008). 
α2 integrin has been demonstrated to be able to regenerate a fully differentiated prostate 
epithelium in immunocompromised mice (Gedye et al., 2009).  Moreover, cells which express 
both α2 and CD133 have a higher proliferative potential, and have a greater ability to 
reconstitute a normal prostate gland (Gedye et al., 2009).  These cells, showing expression of α2 
and CD133, represent a tumor-initiating population within human prostate cancer (Maitland and 
Collins, 2008). 
 
Other Markers for Prostate Cancer Stem Cells 
p63 Basal Cell Marker 
p63 is widely used for identification of normal prostate basal cells (Signoretti et al., 
2000).  It is also selectively expressed in the basal cell compartment of a variety of other 
epithelial tissues (Signoretti et al., 2000).  Since this protein is undetectable in prostate cancer, its 
expression is used for the differential diagnosis between benign and malignant areas of the 
prostate gland (Signoretti et al., 2000), making it a negative marker for prostate cancer.   
 
CD133 Stem Cell Marker 
CD133, also known as PROML1 or prominin, is known to be a stem cell surface antigen 
in several tissues, including the prostate (Choi et al., 2009).  It is a homologue of a mouse cell 
surface transmembrane glycoprotein, Prominin-1, and was originally found on neuroepithelial 
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stem cells in mice (Miki et al., 2007).  It is used extensively to identify normal stem cells and 
cancer stem cells in a variety of tissues, such as hematopoietic, leukemic, neural, brain tumor, 
and most importantly, prostate cells (Miki et al., 2007).  Immunohistochemical studies have been 
performed to study localization of CD133 in the prostate, with the conclusion that CD133 may 
be unable to accurately identify cancer stem cells independently (Sullivan et al., 2008).  The 
distribution of CD133 across the prostate tissue is variable, and appears mostly in epithelial and 
stromal cell-specific, Figure 3 (Sullivan et al., 2008).  However, since expression is seen in both 
benign and neoplastic tissue, (Figure 3), it was deduced that although CD133 may be a stem cell 
marker in the prostate, it may not be able to accurately identify cancer stem cells on its own 
(Sullivan et al., 2008).   
 
 
 
 
 
 
Figure 3. Expression of CD133 in 
Prostate Tissue. 
Immunohistochemistry for CD133 
shows expression in neoplastic tissue 
(A) and benign glands (B and C).  The 
respective negative controls, stained 
with rIgG, are seen in panels D-F.  
Expression is seen to be epithelial-cell 
specific and diffuse in epithelial and 
stromal cells (Sullivan et al., 2008).  
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Trop2 Stem Cell Marker 
Trop2 is a transmembrane tumor-associated calcium signal transducer whose function or 
ligand is not completely known, that is expressed in human epithelia, and frequently upregulated 
in carcinomas (Fornaro et al., 1995; Ohmachi et al., 2006; Fong et al., 2008).  Its expression has 
been reported in both normal and malignant tissue from organs such as kidney, lung, ovary, 
testes, etc (Goldstein et al., 2008).  Trop2 has been recently used to functionally discriminate 
between two basal cell subpopulations in the human prostate (Goldstein et al., 2008).  Though 
not all basal cells exhibit stem cell characteristics, basal cells expressing high levels of Trop2 are 
found to be enriched with in vitro and in vivo stem cell-like characteristics (Goldstein et al., 
2008).  The role of Trop2, though not elucidated in normal and cancer cells, is suggested to be 
directly related to tumorigenicity and invasion of cancer cells (Goldstein et al., 2008).  
18 
 
PROJECT PURPOSE 
 
As discussed in the Background, understanding cancer stem cells is of utmost importance 
in the study and treatment of cancer.  Several models have been presented throughout the years 
for prostate oncogenesis.  The hypothesis being tested by this MQP is that the existence of an 
integrin marker for cancer stem cells can be confirmed by coexpression with known stem cell 
markers.  Human prostate tissue specimens were analyzed by immunohistochemistry for stem 
cell marker Trop-2, as well as for integrins β3 and α2.  Staining for prostate basal cell marker 
p63 was also performed for the identification of cancer cells which lack p63 expression.  Double 
staining was performed for CD133 and α2 to identify potential cancer stem cell candidates.  
Immunofluorescence was performed to show localization of Trop-2 in prostate cancer cells, and 
immunoblotting was performed to analyze potential aberrations of Trop2 elecTrophoretic 
mobility.  I hypothesize coexpression of integrin markers β3 (upregulated in prostate cancer) and 
α2 (upregulated in metastases) with stem cell markers CD133 and Trop-2 in regions negative for 
p63.  This MQP study will identify novel cancer stem cell populations, which can be then 
isolated and characterized, for further studies for research and therapeutic purposes. 
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MATERIALS AND METHODS 
 
Immunohistochemistry (IHC) 
Paraffin-Embedded, Formalin Fixed Sections: (p63, and Trop2) 
 IHC staining was performed on 4µm sections prepared from paraffin-embedded blocks, 
placed on charged glass slides.  The sections were deparaffinized in three changes of xylene for 
10 minutes each.  The slides were then hydrated in an ethanol series for 2 changes of 2 minutes 
each of 100% EtOH, 95% EtOH, 70% EtOH, 50% EtOH, and dH2O.  The sections were then 
incubated in 3% hydrogen peroxide for 5 minutes to remove endogenous peroxidase activity.  
The slides were then blocked for non-specific staining.  Next, the slides were incubated with the 
primary antibody.  An IgG antibody raised in the same animal as the primary antibody was used 
as a negative control.  After a series of 3 washes in PBS, slides were incubated with the primary 
antibody diluted in PBS+0.5% BSA.  Slides were then washed 3 times with PBS + 0.05% 
Tween-20, and incubated with a biotinylated secondary IgG antibody.  The conditions and 
durations for blocking, primary antibody, and secondary antibody incubation varied, and details 
can be seen in Table 2.  Immunoperoxidase staining was performed using horseradish 
peroxidase streptavidin (Vector Labs, SA-5004), at a dilution of 1:100.  The signal was amplified 
using the DAB Substrate-Chromogen System (Zymed Laboratories, Cat. #00-2014).  Finally, the 
slides were counterstained with Mayer’s hematoxylin, and dehydrated by reversing the alcohol 
and xylene series.  Stained tissue sections were examined on an Olympus BX41 microscope and 
photographed using an Olympus DP12 camera.  The IHC staining results were evaluated by Dr. 
Z. Jiang, Dr. L.R. Languino, Dr. H. L. Goel, Dr. M. Trerotola (University of Massachusetts 
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Medical School Departments of Pathology and Cancer Biology) and myself. The details for the 
cases used (Cases 1-15) can be seen in Table 3. 
 
Frozen Sections: (CD133 and α2 Double Staining) 
 IHC staining was performed on 5µm sections prepared from frozen tumors, placed on 
charged glass slides. The sections were fixed in acetone at -20°C for 10 minutes.  The slides 
were then blocked with 0.5% casein and 0.05% thimerosol diluted in TBS for 15 minutes at 
room temperature.  The slides were then incubated with the primary antibody. An IgG antibody 
raised in the same animal as the primary antibody was substituted as a negative control. After a 
series of washes in PBS, slides were incubated with the primary antibody, diluted in PBS+0.1% 
BSA.  Slides were then washed 3 times with PBS, and incubated with a biotinylated secondary 
IgG antibody. Immunoperoxidase staining was performed using horseradish peroxidase 
streptavidin (Vector Labs, SA-5004), at a dilution of 1:100.  The signal was amplified using the 
DAB Substrate-Chromogen System (Zymed Laboratories, Cat. #00-2014).  Finally, the slides 
were counterstained with Mayer’s hematoxylin.  The sections were then dehydrated in an ethanol 
series for 2 changes of 2 minutes each of 50% EtOH, 70% EtOH, 95% EtOH, 100% EtOH, and 
Xylene.  Stained tissue sections were examined on an Olympus BX41 microscope and 
photographed using an Olympus DP12 camera.  The IHC staining results were evaluated by Dr. 
Z. Jiang, Dr. L.R. Languino, Dr. H. L. Goel, (University of Massachusetts Medical School 
Departments of Pathology and Cancer Biology) and myself.  The cases used (Cases 16-21) did 
not have gleason grades available, but were graded by Dr. L.R. Languino and Dr. Z. Jiang. 
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Scoring of Expression 
 For all p63 IHC, expression was scored with a “+” and “-“ system, indicating expression 
or lack of expression in benign and malignant regions.  For all other IHC experiments, 
expression of the marker was seen in both benign and malignant regions.  Thus, staining was 
scored with a “+”, indicating the experiment was successful and yielded specific staining, or a  
“-“, indicating that the experiment did not yield specific staining.  
  
Double Staining 
  All double staining was performed using the Invitrogen PicTure Double Staining Kit (Cat 
No. 87-9999).  The protocol followed was provided by the manufacturer, with aforementioned 
details for paraffin-embedded and frozen sections. α2 expression was seen by the brown HRP 
staining, and CD133 expression was seen by the red Fast-Red staining.  Stained tissue sections 
were examined on an Olympus BX41 microscope and photographed using an Olympus DP12 
camera.  The IHC staining results were evaluated by Dr. Z. Jiang, Dr. L.R. Languino, Dr. H. L. 
Goel, Dr. M. Trerotola (University of Massachusetts Medical School Departments of Pathology 
and Cancer Biology) and myself.  Areas in tissue sections showing both colors, or displaying 
double staining, were targeted as potential stem cells. 
 
Immunofluorescence (IF) 
 Immunofluorescence was performed to examine the localization of Trop2 in PC3 cells 
transfected with Trop2, seeded on fibronectin.  Cells were fixed on coverslips by incubation with 
4% paraformaldehyde diluted in PBS for 5 minutes. To permeabilize the cells, coverslips were 
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incubated with PBS+0.5% Triton for 5 minutes. The coverslips were then blocked with 5% BSA 
diluted in PBS for 20 minutes at room temperature.  The coverslips were then incubated with the 
primary antibody (Trop2 T16) for 20 minutes, at a dilution of 1:80.  After incubation with the 
primary antibody, the coverslips were washed several times with PBS.  Coverslips were then 
incubated with the secondary FITC-conjugated goat anti-mouse antibody and Phalloidin-TRITC 
(1:1000, for Actin staining), in 5% BSA for 20 minutes.  The coverslips were washed three times 
with PBS and mounted with anti fade reagent (Invitrogen, ProLong Gold antifade reagent, cat. 
P36930) for fluorescence microscopy (Olympus IX71). 
 
Immunoblotting 
 Cells used for lysates were PC3-2 prostate cancer cells transfected with Trop2 or empty 
vector, for positive and negative controls, respectively.  These cells do not endogenously express 
Trop2.  Malignant and benign prostate tissue samples were also used for lysates. Cells and 
tissues were lysed in lysis buffer composed of 100 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 1% 
Triton X-100.  Tissue samples were homogenized for 5 minutes until even suspension.  The 
suspension was decanted, and an equal volume of 10% SDS was added to make final 
concentration of 5% SDS.  The samples were mixed and boiled for 5 minutes.  The tissue 
samples were then centrifuged at 14,000 RPM for 20 minutes at 4°C.  The supernatants were 
then collected for BCA total protein assay. 
 Total cellular protein was resolved by SDS-PAGE, transferred onto a PVDF membrane, 
and immunoblotted with mAb to Trop2.  Proteins were separated by 10% SDS-PAGE under non 
reducing conditions, and immunoblotted with an Ab specific to FAK as a loading control.  
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Protein was visualized using an ECL reagent (Boston Bioproducts), and developed using 
autoradiography (ISC Bioexpress).   
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Table 3. Antibody and IHC Details 
Marker Antibody 
Stock 
Concentration 
Dilution Blocking 
Antigen 
Retrieval 
Primary 
Incubation 
Secondary Incubation Reference 
p63 
Santa Cruz 
Biotechnolog
y p63 [4A4] 
200 µg/mL 1:50 
Horse Serum,  
20 minutes 
10mM Sodium 
Citrate Buffer, pH 
6.0 
750W Microwave 
Oven, 15 minutes 
4°C, 
overnight 
Vector Labs, BA-2000 
Biotinylated Anti-
Mouse IgG (H+L), 30 
minutes 
Emanuel et al., 2004 
CD133 
Abcam Rb 
pAb to 
CD133 
ab19898-100 
1 mg/mL 1:400 
Blocking 
solution 
(Invitrogen 
PicTure Kit), 
30 minutes 
- 
4°C, 
overnight 
Biotinylated Anti-
Rabbit IgG Conjugated 
to Alkaline Phosphatase 
(Invitrogen PicTure 
Kit) 
Friedman et al., 2009 
Trop2 
R&D Anti-
Trop2 
AF650 
1 mg/mL 1:200 
1% BSA, 5% 
Rabbit Serum 
in TBS, 1 
hour 
 Microwave Oven, 
8 minutes 
1 hour, RT 
Vector Labs, BA-9500 
Biotinylated Anti-Goat 
IgG (H+L), 1 hour 
Fong et al., 2008 
β3 
Abcam, mAb 
to Integrin 
beta 3 [BV4] 
ab7167-50 
100 µg/mL 
1:50, 
1:100 
Horse Serum,  
20 minutes 
After pressure is 
reached in 
pressure cooker, 3 
minutes 
4°C, 
overnight 
Vector Labs, BA-2000 
Biotinylated Anti-
Mouse IgG (H+L), 30 
minutes 
Neto et al., 2007 
Hybridoma 
Culture 
Supernatant 
AP3   
1:10, 1:5 
Goat Serum, 
45 minutes 
Proteinase K, 
37°C, 30 minutes 
4°C, 
overnight 
Hybridoma Culture 
Supernatant 12CA5, 45 
minutes 
Degrosellier et al., 2009 
Purified 
Antibody 
AP3 
30 µg/mL, 10 
µg/mL 
  
Goat Serum, 
45 minutes 
Proteinase K, 
37°C, 30 minutes 
4°C, 
overnight 
Hybridoma Culture 
Supernatant 12CA5, 45 
minutes 
Degrosellier et al., 2009 
α2 
Santa Cruz 
Biotechnolog
y α2 [HAS-3] 
200 µg/mL 1:10 
TBS + 0.5% 
casein and 
0.05% 
thimerosal, 
15 minutes 
- 
4°C, 
overnight 
Vector Labs, BA-2000 
Biotinylated Anti-
Mouse IgG (H+L), 30 
minutes 
Yoshimura et al., 2009 
25 
 
Table 3. Paraffin-Embedded Formalin Fixed Case Details 
Case 
Tissue 
Type 
Diagnosis A/S/R 
Necrosis 
% 
Lesion 
% 
Stroma 
% 
Gleason Grade 
1 Malignant Adenocarcinoma 74/M/W 0 70 30 7 
2 Malignant Adenocarcinoma 60/M/W 0 30 70 7 
3 Malignant Adenocarcinoma 64/M/W 0 80 20 7 
4 Malignant Adenocarcinoma 68/M/W 0 20 80 6 
5 Malignant Adenocarcinoma 72/M/W 0 30 70 6 
6 Malignant Adenocarcinoma 72/M/W 0 30 70 6 
7 Malignant Adenocarcinoma 78/M/W 0 30 70 7 
8 Malignant Adenocarcinoma 66/M/W 0 30 70 7 
9 Malignant Adenocarcinoma 68/M/W 0 20 80 6 
10 Malignant Adenocarcinoma 52/M/W 0 30 70 7 
11 Malignant Adenocarcinoma 67/M/W 0 20 80 6 
12 Malignant Adenocarcinoma 73/M/W 0 30 70 9 
13 Normal - 51/M/W 0 0 0   
14 Malignant Adenocarcinoma 69/M/W 0 50 50 6 
15 Malignant Adenocarcinoma 70/M/W 0 60 40 7 
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RESULTS 
 
p63 Expression in Benign and Malignant Prostate  
As detailed in the Background section, to study the presence and localization of prostate 
cancer stem cells (CSCs), it is important to include the evaluation of benign glands.  p63 
expression in benign and malignant prostate was studied since p63 is a prostate basal cell marker 
(Signoretti et al, 2000).  p63 was evaluated to discriminate between benign and malignant 
regions of the prostate, as this protein’s expression is limited to basal cells (Signoretti et al., 
2000), enabling us to use it for differential diagnosis. 
Immunohistochemical analysis of p63 expression in benign and malignant human 
prostate tissue specimens was performed.  Strong p63 reactivity was observed in benign prostate 
sections stained with monoclonal 4A4 antibody against p63 (Figure 4A, B, C). The specificity 
of the 4A4 antibody was verified when compared to the negative controls stained with mouse 
IgG (Figure 4D, E, F).  Nuclear staining in prostate tissue was present in basal cells of the 
epithelium of benign areas within the pathogenic prostate glands.  No expression of p63 was 
observed in malignant areas of the prostate cancer specimens (Figure 5). 
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Figure 4. p63 Expression in Benign Prostate Glands 
Analyzed by Immunohistochemistry 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Lack of p63 Expression in Malignant Prostate Cells 
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The p63 results were reproduced and scored using a “+” and “-“ system for ten cases, as 
shown in Table 4.  The case details for these and all subsequent paraffin-embedded cases were 
shown in Table 3, in the Materials and Methods section.  Strong p63 immunoreactivity was 
consistently seen in the epithelium of benign prostate glands.  p63 expression within these 
regions is considered specific to cell type, as it is only expressed in benign basal cells, but is not 
present in surrounding stromal or cancerous cells.  Thus, p63 provided a reliable marker to 
exclude benign prostate cells in future experiments of this MQP. 
 
Table 4. Summary of Immunohistochemical Expression 
of p63 in Benign and Malignant Prostate 
 
Immunohistochemical 
Expression of p63 in 
Benign and Malignant 
Prostate 
  p63 
Case Benign Malignant 
1 + - 
2 + - 
3 + - 
8 + - 
10 + - 
11 + - 
12 + - 
13 + - 
14 + - 
15 + - 
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Trop2 Expression in Benign and Malignant Prostate 
Immunohistochemical analysis of Trop2 expression in benign and malignant human 
prostate tissue specimens was performed based on published studies showing the potential for 
Trop2 to be a stem cell candidate (Goldstein et al., 2008).  Expression was observed in prostate 
sections stained with polyclonal antibody against Trop2 (Figure 6A, B, C).  The specificity of 
the Trop2 antibody was verified when compared to the negative controls stained with goat IgG 
(Figure 6D, E, F).  Trop2 expression was observed in both benign and malignant tissue areas.  
The staining pattern in malignant areas was very similar to that exhibited in benign glands.  
Staining was seen in cells of epithelial origin, but not in stromal cells in benign and malignant 
prostate.  In malignant areas of the prostate, staining was diffuse and cytoplasmic (Figure 7, 
Panels A, B, C). 
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Figure 6. Analysis of Trop2 Expression in Benign Prostate Glands by Immunohistochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Analysis of Trop2 Expression in Malignant Prostate Cells by Immunohistochemistry. 
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It can be concluded from these results that Trop2 is expressed in both benign and 
malignant prostate cancer.  The IHC results for all the staining performed on paraffin-embedded 
sections for Trop2 are summarized in Table 5.  A “+” indicates that staining was visible in both 
benign and malignant areas, and a “-“ indicates that no staining was visible at all. The case 
details can be seen in Table 3 in the Materials and Methods section. 
Table 5. Summary of the Expression of Trop2 
in Prostate Tissue Specimens 
Expression of Trop2 in Prostate Tissue Specimens 
Case Trop2 
1 - 
4 + 
5 + 
6 + 
7 + 
8 + 
9 + 
10 + 
13 - 
14 + 
15 + 
 
Next, immunoblotting analysis of Trop2 expression in benign and prostate tissue, as well 
as PC3 and PC3-Trop2 cell lysates, was performed to test for protein expression levels, and 
possible differences between benign and malignant prostate tissue (Figure 8).  PC3 cells, which 
do not endogenously express Trop2 were used as a negative control, while the same cell line 
transfected with Trop2 was used as a positive control.   The findings indicate that Trop2 is 
expressed in both benign and malignant prostate tissue.  The difference in expression levels 
observed within the tissue lysates are not indicative of expression levels as a whole.  
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Figure 8. Trop2 Immunoblot. 
 
 
Studies have shown that Trop2 expression correlates with poor prognosis in human 
carcinomas (Goldstein et al., 2008), suggesting that it can play an important role in tumor 
invasion and migration.  Immunofluorescence was performed on the aforementioned PC3 cells 
seeded on fibronectin to study the expression and localization of Trop2 (Figure 9A).  Trop2 was 
found to strongly co-localize with actin in discrete membrane rims (Fig 9B, C).  Since actin is 
actively involved in the regulation of cellular movements on substrates, like fibronectin, these 
results support a role of Trop2 in modulation of PC3 migration. 
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Figure 9. Trop2 & Actin Immunofluorescence. 
 
 
 
 
 
 
 
 
Integrin Expression in Frozen Prostate Tissue Specimens 
From the aforementioned results, it can be said that Trop2 cannot be used as a cancer 
stem cell marker, as it shows diffuse expression.  According to recent studies, tumor cells 
expressing α2 integrin and CD133 represent subpopulations with high proliferation potential 
(Collins et al., 2005).  Single α2 IHC was performed as a pre-screen to enable subsequent double 
staining of α2 and CD133, to isolate cancer stem cells.  Immunohistochemistry was performed 
on paraffin-embedded sections to visualize integrin expression in human prostate tissue (data not 
shown).  However, no expression could be seen for either α2 or β3, as the antibody does not 
work on paraffin-embedded sections.    
IHC was then performed on frozen sections, with successful results only for α2. 
Expression was observed in frozen prostate sections stained with monoclonal HAS-3 antibody 
against α2 (Figure 10, A-C).  The specificity of the α2 antibody was verified when compared to 
the negative controls stained with mouse IgG (Figure 10, D-F).   α2 expression is diffuse and 
can be seen in the epithelial cells of benign glands, as well as in a cancerous region. The 
expression appears to be at a uniform level throughout the prostate tissue. Our results are also in 
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disagreement with results seen by Nagle et al., as expression levels were the same in both benign 
prostate and adenocarcinoma.  
Figure 10. α2 Expression in Frozen Prostate Tissue 
Analyzed by Immunohistochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
With successful staining visible on frozen prostate sections, double staining with α2 and 
CD133 to isolate cancer stem cells was possible. Double staining reveals coexpression of α2 
(brown color) and CD133 (red color) within the same prostate tissue section (Figure 11, A,B,C).  
The arrows indicate regions which are stem cell candidates, due to heavy expression of both α2 
and CD133 (Gedye et al., 2009). 
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Figure 11. Double Immunohistochemical Staining to Analyze the 
Co-Expression of α2 and CD133 in Frozen Prostate Tissue 
 
It cannot be said with certainty whether cancer stem cells were identified, as only 1 of the 
6 cases tested showed cancer regions. The double staining revealed cells with high expression of 
CD133 and α2, characteristics of cells with high clonogenicity (Maitland and Collins, 2008). 
These cells are potential stem cell candidates, because expression levels are high for both CD133 
and α2.  Overall, the single staining of α2 was performed on 6 cases, 1 of which had malignant 
regions.  Double staining with CD133, was performed on a total of 6 frozen cases. The IHC 
results for all the staining performed on frozen sections for CD133 and α2 are summarized in 
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Table 6.  A “+” indicates that staining was visible, and a “-“ indicates that no staining was 
visible at all.  
Table 6. Summary of the Expression of α2 and CD133 
in Frozen Prostate Tissue Specimens 
Expression of Markers in Frozen Prostate 
Tissue Specimens 
Case 
α2 CD133 & α2 
Coexpression 
Benign Malignant 
16 +   + 
17 +   + 
18 +   + 
19 +   + 
20 +   + 
21 + + + 
 
Black denotes not tested. 
 
β3 Immunohistochemistry 
 Attempts were made to perform IHC on both paraffin-embedded and frozen sections for 
β3 integrin.  Various methods of antigen retrieval and different antibodies were tested (as per 
Table 2), but we could not see any positive specific staining for β3 expression, even in known 
malignant areas (data not shown).  
 
Paraffin-Embedded vs. Frozen Sections  
 It is important to note that expression for both integrins α2 and β3 could not be detected 
on paraffin-embedded sections.  This lead to the belief that integrin antigens are better preserved 
in frozen tissue than in their paraffin-embedded counterparts. 
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DISCUSSION 
Treatment against the proliferation of cancer stem cells may well be the next step of 
cancer therapy.  In this MQP, various known and potential markers were analyzed to enable us to 
potentially isolate prostate cancer stem cells in the future.  The hypothesis tested by this MQP 
was that the existence of an integrin marker for cancer stem cells will co-express with known 
stem cell markers.  We saw that Trop2 and α2 staining was diffuse, thus they could not be used 
independently as cancer stem cell markers.  However, through our observed coexpression of 
CD133 and α2, we identified stem cells which could be potential cancer stem cells.  
The study of p63 expression plays an important role in the study of prostate cancer.  An 
established prostate basal cell marker, p63 is used in the differential diagnosis between benign 
and malignant areas of the prostate (Signoretti et al., 2000).  p63 expression was seen in basal 
cells of the prostate epithelium which enabled us to identify areas of the prostate tissue specimen 
that were benign, versus the cancerous regions.  It was consistently seen that p63 expression was 
lacking in malignant areas of the prostate, thus enabling us to conclude that p63 is an excellent 
negative marker for prostate cancer.    
CD133, a known stem cell surface antigen for prostate tissue (Choi et al., 2009), played 
an important role in this project to identify potential CSCs.  As previously suggested, CD133 can 
be used in combination with other markers to identify CSCs.  In contrast, Trop2 was seen to 
display diffuse expression in both benign prostate epithelium and cancer, thus it cannot be used 
as a CSC marker.   
As previously stated, the focus of this MQP was the characterization of an integrin 
markers, such as α2 (Maitland and Collins, 2008) or β3 (Goel et al., 2008), for the identification 
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of CSCs.  However, it was seen that α2 expression was diffuse, and thus it could not be used to 
identify CSCs. 
Future Experiments 
 Although in this MQP study we were unable to definitively identify prostate cancer stem 
cells, we took a clear step forward towards this goal. We established that α2 and Trop2 cannot be 
used in the identification of CSCs, and that CD133 would need to be studied with another marker 
to identify CSCs.  Future studies would involve isolating CSCs by fluorescence activated cell 
sorting using CD133 in combination with other markers, and analyzing their potential for multi-
lineage differentiation and tumor growth. 
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